In pre-ruminant calves with rotavirus-induced villous atrophy and crypt hyperproliferation, Tannalbin Veterinary Grade API is incorporated into oral rehydration adjuncts as an intestinal surface stabiliser that precipitates damaged mucosal proteins rather than as an antimicrobial agent. Formulation input for calf oral powders is established at 2–5 g per animal per single dose, repeated at 12-hour intervals, with the API fraction in the powder matrix held at 20–40% w/w; for a 50 kg calf this corresponds to approximately 40–100 mg/kg bodyweight. Batch release for the oral powder follows Ph. Eur. 2.9.5 uniformity of mass, Ph. Eur. 2.9.12 sieve test, Ph. Eur. 5.1.4 microbiological quality of non-sterile oral preparations, and VICH GL18 residual solvent controls for the API. Production-scale dry blending is performed in a 5:1 V-shell blender with 0.25% w/w colloidal silicon dioxide as glidant; the blend is passed through an oscillating sieve with 0.500 mm aperture before sachet filling. Finished units for this application are 10 g and 20 g LDPE/Alu/PE sachets, 250 g and 500 g HDPE jars, and 1 kg bulk packs.

During storage and handling, the loss on drying must remain below 3.0% because moisture above 60% RH accelerates hydrolysis of gallotannin ester bonds in the complex, resulting in darkening, reduced astringency, and caking. When the powder is diluted in milk replacer, the fat fraction competes with hydrophobic regions of the albumin-tannate complex and reduces contact with the intestinal mucosa; the powder is therefore predispersed in 200 mL of water at 20–25 °C for 5 minutes before addition to the liquid feed. Published data for this specific fat-competition configuration in calves is limited, and the predispersion step is controlled by visual absence of sediment rather than by a pharmacopoeial method. In a production failure mode observed on a continuous powder-filling line, static charge from lactose monohydrate at relative humidity below 40% caused sachet wall adhesion and high net-weight variability; installation of an ionising bar before the forming collar reduced reject rates to below 0.5% of filled units.

What Limits Uniform Distribution in Swine Drinking Water Granules?

For weaned piglets with enterotoxigenic Escherichia coli F4-associated post-weaning diarrhea, Tannalbin Veterinary Grade API is formulated as a water-dispersible granule to suppress dusting and to improve proportioner dosing reliability across a batch. The target addition in drinking water is 1.0–2.0 g/L, typically administered for 5–7 days; for individual oral dosing, 0.5–2.0 g per animal per day is applied in divided doses. The granulation process uses a fluid-bed top-spray system with a 5% w/w povidone K30 binder solution in purified water, inlet air at 60–65 °C, product temperature held at 35–40 °C, and spray rate of 80–120 g/min for a 10 kg batch. The dried granules are sieved to 1.0 mm, and the fines fraction below 0.150 mm is limited to ≤15% because excessive fines float on the water surface in stock tanks and cause inconsistent dosing through proportioner pumps. Final loss on drying is controlled at 1.8–2.5% to maintain granule hardness without promoting hydrolytic degradation.

Compliance for this application is anchored to Regulation (EU) 2019/6 for veterinary medicinal products, with batch release tests under Ph. Eur. 2.9.12 sieve analysis, Ph. Eur. 2.6.12 and 2.6.13 microbial enumeration, and VICH GL18 residual solvent assessment. The dosage forms packed for distribution are 100 g and 500 g HDPE jars, 1 kg Alu/PE pouches, and 5 kg medicated premix bags for incorporation into creep feed at 1–4 kg/tonne Tannalbin API. On a production-scale proportioning system operating at 1–5% stock solution injection, granules with a median particle size below 0.300 mm were observed to hydrate too rapidly and form a gel-like film on the medicator screen, reducing flow through the dosing port; raising the D50 to 0.450–0.600 mm eliminated screen fouling but increased wetting time to 120 seconds in a 500 mL beaker under 300 rpm magnetic stirring. Published data for this specific particle-size threshold in Tannalbin drinking-water granules is limited, and the operating range should be verified on the target proportioning equipment.

Poultry Drinking Water Suspensions and the Problem of Nipple-Line Sedimentation

During necrotic enteritis episodes in broiler and turkey flocks, the API is administered through drinking water as a suspension rather than a true solution because the albumin-tannate complex is poorly water-soluble and settles without the correct suspending system. Addition levels are commonly 0.5–1.0 g/L of final drinking water for 5–7 days; liquid concentrates are prepared at 20% w/v using 0.25–0.50% w/v xanthan gum and 0.10% w/v citric acid in purified water. The concentrate is mixed in a high-shear rotor-stator disperser at 3000 rpm for 15 minutes, then held for 2 hours and remixed at 1500 rpm for 5 minutes before filling. The API particle size is controlled at a D50 of 10–20 µm by laser diffraction according to Ph. Eur. 2.9.31; particles above 50 µm are excluded because they settle in nipple drinker lines and create blockages that reduce water flow in mechanically ventilated houses.

Release testing for the liquid oral form uses Ph. Eur. 5.1.4 microbiological quality, Ph. Eur. 2.9.12 for re-dispersibility, and Regulation (EU) 2019/6 where the product is classified as a veterinary medicinal product. Pack sizes supplied to poultry houses are 100 mL, 500 mL, and 1 L high-density polyethylene bottles with tamper-evident caps, plus 5 L jerrycans for large flocks. A production failure mode recorded on a commercial filling line involved xanthan gum hydration gradients when the disperser was charged too quickly; the resulting lumps were not visible after filling but appeared as translucent fish-eye particles after 24 hours of storage. The corrective action was to screen the xanthan gum through a 0.500 mm sieve into the vortex at 3000 rpm and to maintain water temperature at 20–25 °C during hydration.

When API Content Exceeds 40% w/w in Tablet Cores

Companion animal gastroenteritis requiring sustained intestinal astringency is treated with compressed tablets or filled capsules containing Tannalbin Veterinary Grade API at API fractions high enough to avoid excessively large units for small patients. For dogs, the tablet formulation targets 250–500 mg Tannalbin per unit in a total core weight of 750 mg, equivalent to 33–67% w/w; for cats, capsules are filled with 100–250 mg API in a 350–500 mg fill weight. Direct compression is used because wet granulation of the tannin complex can initiate darkening and reduce astringency; the powder blend contains microcrystalline cellulose PH102 at 30–55% w/w, croscarmellose sodium 2.0% w/w, and magnesium stearate 0.5% w/w. Tablets are compressed on a rotary press with 10 mm round concave tooling at 10–15 kN compression force; ejection force is kept below 500 N to avoid tablet picking. Hardness is controlled at 70–100 N and disintegration at <15 minutes by Ph. Eur. 2.9.1.

At API contents above 40% w/w, the elastic recovery of the albumin-tannate complex increases and produces edge capping unless a precompression stage is used; the tablet press is therefore set with a precompression force of 2–4 kN and main compression not exceeding 15 kN. Release testing includes Ph. Eur. 2.9.40 uniformity of dosage units, Ph. Eur. 2.2.32 loss on drying, VICH GL18 residual solvents, and FDA 21 CFR Part 211 for finished product shipped to markets requiring cGMP. Packaging configurations for the small-animal market include 10-tablet and 30-tablet PVC/PVDC/aluminium blisters, 60-tablet HDPE bottles with desiccant, and 100-capsule HDPE jars. In a batch-scale troubleshooting event on a rotary press, a moisture content below 2.0% caused static adhesion to the punch faces, while moisture above 3.5% caused sticking and increased friability; the in-process range was therefore set at 2.0–3.5% loss on drying.

During winter calving when milk replacer osmolality is already elevated by oral electrolytes, the API is layered into milk replacer premixes to deliver an astringent effect without adding a separate drenching event. The premix is formulated at 10% w/w Tannalbin on a lactose monohydrate carrier with 0.5% w/w hydrophobic fumed silica to reduce segregation during pneumatic transfer; the final inclusion of this premix in liquid milk replacer is 20–50 kg/tonne of dry matter. Mixing is performed in a horizontal ribbon mixer at 25 rpm for 10 minutes, and blend uniformity is monitored by a 10-sample assay with coefficient of variation ≤5%. The premix is passed through a 0.250 mm screen before bagging. The premix is filled into 5 kg and 25 kg multiwall paper bags with PE liner; small-volume 1 kg pouches are used for calf rearers treating 20–30 calves per batch.

Compliance for the premix follows Regulation (EU) 2019/6 when used under veterinary prescription, FAMI-QS code of practice for feed additive and premix operators, and Ph. Eur. 2.9.5 uniformity of mass for sachet-packed units. The premix must not be combined with alkaline electrolytes or buffering agents above pH 8.0 because the tannate ester bonds hydrolyse and release free tannic acid, which reduces palatability and can cause feed refusal. Published data for this specific incompatibility in calf milk replacer is limited; the operational boundary is derived from gallotannin ester hydrolysis chemistry rather than from a controlled field trial.

For compounding pharmacies serving referral practices, Tannalbin Veterinary Grade API is used for patient-specific oral preparations when licensed tablet strengths are unsuitable for miniature breeds, neonatal foals, or exotic species. The compounding addition ratio is calculated from the prescribed dose, commonly 10–40 mg/kg in dogs and cats when supported by the prescribing veterinarian, and 20–50 mg/kg in calves and lambs for oral administration; the API is incorporated into oral powder, capsule, or suspension bases at 5–20% w/w of the final compounded preparation. Compounding compliance follows USP <795> for nonsterile preparations, Ph. Eur. 2.6.12/2.6.13 for microbial limits, and applicable veterinary prescribing regulations under Regulation (EU) 2019/6; sterile injectable compounding is not supported because the albumin-tannate complex is practically insoluble in water and no published data for injectable tolerance are referenced. The production process uses geometric dilution in a glass mortar with lactose monohydrate, followed by capsule filling on a 100-hole manual capsule machine for small batches, or suspension preparation by levigation with glycerin before incorporation into a syrup vehicle.

Dispensed preparations are packaged as patient-specific capsules in 100 mg, 250 mg, and 500 mg strengths, oral suspensions in 30 mL and 60 mL amber bottles, and oral powders in 2 g and 5 g unit-dose sachets. A batch-scale constraint observed in compounding practice is that mixing the API with highly hygroscopic carriers such as sorbitol above 10% w/w causes caking within 48 hours at 60% RH; the compounded powder is therefore packed with silica gel desiccant and labelled with a beyond-use date not exceeding 90 days. When the compounded oral suspension is prepared, the API is levigated with glycerin at 10% w/w of the final volume before addition of a methylcellulose-containing vehicle; this step reduces floating of the tannin complex on the surface. Batch records include USP <795> documentation for beyond-use dating and Ph. Eur. 2.9.1 disintegration testing for capsules. Published data for this specific compounding configuration in exotic species is limited, and dose verification against the primary literature is required before dispensing.